Sonic Healthcare Ltd

SHL: XASX (AUS)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
^NSLOCK|&!>FLOCK|%XkQRY

Sonic Healthcare: Shares Undervalued as Firm Tracks to Expectations

Narrow-moat Sonic reported constant-currency revenue and EBITDA growth of roughly 10% for the first four months of fiscal 2025, both meeting our expectations. Sonic reiterated fiscal 2025 EBITDA guidance of AUD 1.70 to AUD 1.75 billion, implying 8% growth at the midpoint of fiscal 2024, and compares with our unchanged fiscal 2024 EBITDA forecast of 1.74 billion. Our long-term estimates are also unchanged, including our midcycle EBITDA margin forecast of 22% compared with 19% in the second half of fiscal 2024.

Sponsor Center